adenine has been researched along with Hematologic Malignancies in 28 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to evaluate the efficacy of five oral nucleos(t)ide analogues (NAs), including lamivudine, entecavir, adefovir, telbivudine and tenofovir, for the prevention of hepatitis B virus (HBV) reactivation and HBV-related complications in chronic hepatitis B virus (CHB) infected patients with hematological malignancies receiving chemotherapy or hematopoietic stem cell transplantation (HSCT) by network meta-analysis." | 4.95 | Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. ( Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ, 2017) |
| "This was an open-label, multicenter, phase-1 study to evaluate the drug interaction between steady-state ibrutinib and moderate (erythromycin) and strong (voriconazole) CYP3A inhibitors in patients with B-cell malignancies and to confirm dosing recommendations." | 2.87 | A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. ( Chauhan, V; Córdoba, R; de Jong, J; De Wilde, S; de Zwart, L; Hellemans, P; Jiao, J; Manikhas, G; Masterson, T; Myasnikov, A; Osmanov, D; Ouellet, D; Panizo, C; Patricia, D; Snoeys, J; Sukbuntherng, J, 2018) |
| " Furthermore, the nanoformulations studied to increase ibrutinib bioavailability are reported." | 2.72 | Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. ( Brullo, C; Russo, E; Spallarossa, A; Tasso, B; Villa, C, 2021) |
| "Increased infections have been observed in patients taking ibrutinib." | 2.58 | Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. ( Pauff, JM; Satyanarayana, G; Talbott, M; Tillman, BF; Warner, JL, 2018) |
| "Overall, AF and bleeding are manageable clinical events in patients receiving IB, not requiring drug interruption in most cases." | 2.58 | Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. ( Boriani, G; Corradini, P; Cuneo, A; Falanga, A; Foà, R; Gaidano, G; Ghia, PP; Marasca, R; Martelli, M; Massaia, M; Mauro, FR; Minotti, G; Molica, S; Montillo, M; Pinto, A; Tedeschi, A; Vitolo, U; Zinzani, PL, 2018) |
| " phase I/II trials have been conducted to evaluate the dosing schedules and activity of this agent." | 2.58 | BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review). ( He, W; Hu, H, 2018) |
| " However, BTKi have a range of drug-drug and drug-food interactions, which may alter drug efficacy and/or increase toxicity." | 1.56 | Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management. ( Fancher, KM; Pappacena, JJ, 2020) |
| "Low-grade bleeding was more common in ibrutinib-treated than comparator-treated patients (35% and 15%), and early low-grade bleeding was not associated with MH." | 1.51 | Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. ( Bista, A; Boornazian, L; Brown, JR; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Cramer, P; Cymbalista, F; Dilhuydy, MS; Dreyling, M; Ewer, MS; Fraser, G; Ghia, P; Graef, T; Jaeger, U; Liu, EY; Mahler, M; Moslehi, J; O'Brien, SM; Reddy, V; Rule, S; Shanafelt, TD; Treon, S; Valentino, R; Vempati, R; Yang, H, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 20 (71.43) | 24.3611 |
| 2020's | 8 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Egger, M | 1 |
| Gornicec, M | 1 |
| Wölfler, A | 1 |
| Lembeck, AL | 1 |
| Tinchon, C | 1 |
| Maderdonner, M | 1 |
| Prattes, J | 1 |
| Kander, EM | 1 |
| Zhao, Q | 1 |
| Bhat, SA | 1 |
| Hirsch, J | 1 |
| Byrd, JC | 3 |
| Ooka, L | 1 |
| Wiczer, T | 2 |
| Woyach, JA | 2 |
| Awan, FT | 1 |
| Rogers, KA | 2 |
| Wang, TF | 1 |
| Dickerson, T | 1 |
| Waller, A | 1 |
| Philippon, J | 1 |
| Porter, K | 1 |
| Haddad, D | 1 |
| Guha, A | 1 |
| Bhat, S | 1 |
| Awan, F | 1 |
| Addison, D | 1 |
| Lewis, T | 1 |
| Corcoran, DB | 1 |
| Thurston, DE | 1 |
| Giles, PJ | 1 |
| Ashelford, K | 1 |
| Walsby, EJ | 1 |
| Fegan, CD | 1 |
| Pepper, AGS | 1 |
| Miraz Rahman, K | 1 |
| Pepper, C | 1 |
| Cordoba, R | 2 |
| Fancher, KM | 1 |
| Pappacena, JJ | 1 |
| Danilov, AV | 1 |
| Persky, DO | 1 |
| Tazi, I | 1 |
| Ciuculete, DC | 1 |
| Popescu, RA | 1 |
| Dan, GA | 1 |
| Brullo, C | 1 |
| Villa, C | 1 |
| Tasso, B | 1 |
| Russo, E | 1 |
| Spallarossa, A | 1 |
| Zhang, MY | 1 |
| Zhu, GQ | 1 |
| Zheng, JN | 1 |
| Cheng, Z | 1 |
| Van Poucke, S | 1 |
| Shi, KQ | 1 |
| Huang, HH | 1 |
| Chen, FY | 1 |
| Zheng, MH | 1 |
| Schaffer, M | 1 |
| Chaturvedi, S | 1 |
| Davis, C | 1 |
| Aquino, R | 1 |
| Stepanchick, E | 1 |
| Versele, M | 1 |
| Liu, Y | 1 |
| Yang, J | 1 |
| Lu, R | 1 |
| Balasubramanian, S | 1 |
| Garside, J | 1 |
| Healy, N | 1 |
| Besson, H | 1 |
| Hermans, R | 1 |
| MacDougall, F | 1 |
| Lestelle, D | 1 |
| Diels, J | 1 |
| Iraqi, W | 1 |
| Chamilos, G | 1 |
| Lionakis, MS | 1 |
| Kontoyiannis, DP | 1 |
| Snijder, B | 1 |
| Vladimer, GI | 1 |
| Krall, N | 1 |
| Miura, K | 1 |
| Schmolke, AS | 1 |
| Kornauth, C | 1 |
| Lopez de la Fuente, O | 1 |
| Choi, HS | 1 |
| van der Kouwe, E | 1 |
| Gültekin, S | 1 |
| Kazianka, L | 1 |
| Bigenzahn, JW | 1 |
| Hoermann, G | 1 |
| Prutsch, N | 1 |
| Merkel, O | 1 |
| Ringler, A | 1 |
| Sabler, M | 1 |
| Jeryczynski, G | 1 |
| Mayerhoefer, ME | 1 |
| Simonitsch-Klupp, I | 1 |
| Ocko, K | 1 |
| Felberbauer, F | 1 |
| Müllauer, L | 1 |
| Prager, GW | 1 |
| Korkmaz, B | 1 |
| Kenner, L | 1 |
| Sperr, WR | 1 |
| Kralovics, R | 1 |
| Gisslinger, H | 1 |
| Valent, P | 1 |
| Kubicek, S | 1 |
| Jäger, U | 1 |
| Staber, PB | 1 |
| Superti-Furga, G | 1 |
| Tillman, BF | 1 |
| Pauff, JM | 1 |
| Satyanarayana, G | 1 |
| Talbott, M | 1 |
| Warner, JL | 1 |
| Hammond, SP | 1 |
| Chen, K | 1 |
| Pandit, A | 1 |
| Davids, MS | 1 |
| Issa, NC | 1 |
| Marty, FM | 1 |
| Boriani, G | 1 |
| Corradini, P | 1 |
| Cuneo, A | 1 |
| Falanga, A | 1 |
| Foà, R | 1 |
| Gaidano, G | 1 |
| Ghia, PP | 1 |
| Martelli, M | 1 |
| Marasca, R | 1 |
| Massaia, M | 1 |
| Mauro, FR | 1 |
| Minotti, G | 1 |
| Molica, S | 1 |
| Montillo, M | 1 |
| Pinto, A | 1 |
| Tedeschi, A | 1 |
| Vitolo, U | 1 |
| Zinzani, PL | 1 |
| He, W | 1 |
| Hu, H | 1 |
| de Jong, J | 1 |
| Hellemans, P | 1 |
| De Wilde, S | 1 |
| Patricia, D | 1 |
| Masterson, T | 1 |
| Manikhas, G | 1 |
| Myasnikov, A | 1 |
| Osmanov, D | 1 |
| Panizo, C | 1 |
| de Zwart, L | 1 |
| Snoeys, J | 1 |
| Chauhan, V | 1 |
| Jiao, J | 1 |
| Sukbuntherng, J | 1 |
| Ouellet, D | 1 |
| Nastoupil, LJ | 1 |
| Prasad, V | 1 |
| Flowers, CR | 1 |
| Mock, J | 1 |
| Kunk, PR | 1 |
| Palkimas, S | 1 |
| Sen, JM | 1 |
| Devitt, M | 1 |
| Horton, B | 1 |
| Portell, CA | 1 |
| Williams, ME | 1 |
| Maitland, H | 1 |
| Brown, JR | 1 |
| Moslehi, J | 1 |
| Ewer, MS | 1 |
| O'Brien, SM | 1 |
| Ghia, P | 1 |
| Cymbalista, F | 1 |
| Shanafelt, TD | 1 |
| Fraser, G | 1 |
| Rule, S | 1 |
| Coutre, SE | 1 |
| Dilhuydy, MS | 1 |
| Cramer, P | 1 |
| Jaeger, U | 1 |
| Dreyling, M | 1 |
| Treon, S | 1 |
| Liu, EY | 1 |
| Chang, S | 1 |
| Bista, A | 1 |
| Vempati, R | 1 |
| Boornazian, L | 1 |
| Valentino, R | 1 |
| Reddy, V | 1 |
| Mahler, M | 1 |
| Yang, H | 1 |
| Graef, T | 1 |
| Burger, JA | 1 |
| Ezad, S | 1 |
| Khan, AA | 1 |
| Cheema, H | 1 |
| Ashraf, A | 1 |
| Ngo, DTM | 1 |
| Sverdlov, AL | 1 |
| Collins, NJ | 1 |
| Prins, RC | 1 |
| Burke, RT | 1 |
| Tyner, JW | 1 |
| Druker, BJ | 1 |
| Loriaux, MM | 1 |
| Spurgeon, SE | 1 |
| Liu, N | 1 |
| Hoogendoorn, S | 1 |
| van de Kar, B | 1 |
| Kaptein, A | 1 |
| Barf, T | 1 |
| Driessen, C | 1 |
| Filippov, DV | 1 |
| van der Marel, GA | 1 |
| van der Stelt, M | 1 |
| Overkleeft, HS | 1 |
| Smithson, CR | 1 |
| Schneider, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies: Next Generation Personal Hematology[NCT04470947] | 150 participants (Anticipated) | Observational [Patient Registry] | 2020-06-10 | Recruiting | |||
| Pharmacoscopy-guided Clinical Standard-of-care in Relapsed/Refractory Acute Myeloid Leukemia, a Randomized Phase-2 Clinical Trial[NCT06138990] | 82 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| A Prospective Investigator-initiated Translational Study Evaluating Individualized Treatment Regiments Based on Respective Biomarker Analyses for Refractory Leukemia and Lymphoma Patients[NCT03096821] | 143 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410] | 40 participants (Actual) | Observational [Patient Registry] | 2018-12-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for adenine and Hematologic Malignancies
| Article | Year |
|---|---|
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials a | 2021 |
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chemistry, Pharmaceutical; COVID-19 Drug Treatment; Dr | 2021 |
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepa | 2017 |
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2018 |
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Topics: Adenine; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Hema | 2018 |
BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review).
Topics: Adenine; Apoptosis; Hematologic Neoplasms; HSP90 Heat-Shock Proteins; Humans; Molecular Targeted The | 2018 |
Ibrutinib: a new targeted therapy for hematologic cancers.
Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Interactions; Hematologic Neoplasms; | 2015 |
6 trials available for adenine and Hematologic Malignancies
| Article | Year |
|---|---|
Hypertension and incident cardiovascular events following ibrutinib initiation.
Topics: Adenine; Aged; Antihypertensive Agents; Female; Heart Diseases; Hematologic Neoplasms; Humans; Hyper | 2019 |
PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies.
Topics: Adenine; Comparative Effectiveness Research; Data Collection; Databases, Factual; Hematologic Neopla | 2018 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Risk of hepatitis B virus reactivation in patients treated with ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Female; Follow-Up Studies; Hematologic Neoplasms; Hepatitis B; Hep | 2018 |
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
Topics: Adenine; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Ibrutinib-related atrial fibrillation: A single center Australian experience.
Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Australia; Female; Hematologic Neoplasms; Hos | 2019 |
15 other studies available for adenine and Hematologic Malignancies
| Article | Year |
|---|---|
Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria.
Topics: Adenine; Animals; Antifungal Agents; Austria; Hematologic Neoplasms; Humans; Incidence; Invasive Fun | 2022 |
Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Hematologic Neoplasms; Hemorrhage; Humans; Incidence; Middl | 2019 |
Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chloramb | 2019 |
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
Topics: Adenine; Animals; Apoptosis; Benzodiazepines; Bortezomib; Hematologic Neoplasms; Leukemia, Lymphocyt | 2021 |
Bringing hospital care closer to patients amidst COVID-19.
Topics: Adenine; Betacoronavirus; Checklist; Coronavirus Infections; COVID-19; Hematologic Neoplasms; Humans | 2020 |
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Citrus paradisi; Citrus sinensis; Comorbid | 2020 |
[Antineoplasic drug repurposing in hematology for COVID-19 treatment].
Topics: Adenine; Aniline Compounds; COVID-19 Drug Treatment; Drug Repositioning; Hematologic Neoplasms; Huma | 2021 |
Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis.
Topics: Adenine; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Hematologic Neoplasms; Hemorrha | 2021 |
Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2018 |
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
Topics: Adenine; Aged; Aged, 80 and over; Female; Fungi; Hematologic Neoplasms; Humans; Immunosuppressive Ag | 2018 |
The need to assess financial adverse events.
Topics: Adenine; Child; Costs and Cost Analysis; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperidin | 2018 |
Risk of Major Bleeding with Ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Follow-Up Studies; Hematologic Neop | 2018 |
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Topics: Adenine; Aged; Female; Hematologic Neoplasms; Hemorrhage; Humans; Incidence; Male; Middle Aged; Pipe | 2019 |
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Imm | 2013 |
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Hematologic Neoplasms; Humans; Molecular Probes; Nethe | 2015 |